This week, we examine the threat of human papilloma virus — or HPV — to our bodies and the rationale for protecting our kids and ourselves from its potential to ...

The National Agency for Food and Drug Administration and Control (NAFDAC) has directed the immediate withdrawal of multi-dose Artemether/Lumefantrine dry ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion to Acoziborole Winthrop (acoziborole) as a single-dose oral treatment for both ...

Casey Means answered questions about the abortion pill, birth control, and vaccines out of both sides of her mouth.

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

Key Takeaways Consistent oral hygiene practices are crucial for preventing dental issues. Regular dental check-ups help ...

An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformin, the phase III ...

"Dosing the first patient in Phase III represents a major milestone for MDR-001 and for AI-enabled drug development," said Zhangming Niu, Founder and Chief Executive Officer of MindRank. "We believe ...

A new pill could help patients lose more weight and gain better control of their blood sugar levels than current weight loss medications, a promising new study has found.

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 ...

NEWARK, CA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended ...

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this ...